RAPPRapport Therapeutics, Inc. Common Stock
The Read
Historically, RAPP stock has shown high volatility before FDA decisions with moves up to about 43% driven by positive clinical updates, but FDA-related catalysts have not yet resolved, and recent earnings events with RAP-219 trial updates caused mixed reactions including 4–12% moves mostly tied to trial progress and cash runway concerns rather than direct FDA approvals.
The schedule
- Mon9Nov
- Wed23Dec
- Wed23Dec
By mid-October 2026, Rapport is likely to provide a more substantive RAP-219 Phase 3 enrollment milestone and trial optimization update, including geographic mix and interim power assumptions. From a base price of $26.00, confirmation that enrollment is ahead of plan and that the trial is sized and powered for competitive labeling could drive the stock up to $33.00, while a slower pace, high screen-failure rates, or design changes could cut confidence and send shares toward $33.00.
- Wed23Dec
RAP-219 Phase 3 initiation is expected around May 12, 2026, confirming the transition to a pivotal program in focal epilepsy and generalized seizures. At a base price of $39.93, successful site activation and a clean protocol update could justify a rerating toward $44.00, while any delay, safety signal, or enrollment overhang could drive shares back toward $44.00 as investors reassess execution risk at a stretched valuation.
- Sun10Jan
With RAPP trading near its 52-week high of $39.93 and Phase 3 initiation for RAP-219 imminent, the likelihood of a dilutive secondary equity offering is elevated. An opportunistic capital raise would secure the balance sheet but dilute current equity, risking a pullback toward $41.50. Conversely, securing non-dilutive partnership funding could push the stock to $41.50.
- Sun10Jan
The Q2 2026 print will center on the execution of RAP-219's Phase 3 initiation. Assuming the market is absorbing a prior equity raise, focus will shift to enrollment timelines and cash burn guidance. A swift enrollment pace without outsized R&D bloat could lift the stock to $37.00, while delays or higher-than-expected cash burn could trigger a slide to $26.00.
- Sun10Jan
The Q4 print will set the stage for RAP-219's pivotal clinical readouts. Management's guidance on data timing will dictate market positioning. A confirmed, near-term schedule for topline data will invite speculative inflows targeting $37.50, while vague timelines or guided delays will prompt aggressive de-risking toward $37.50.
- Mon10May
Past
- Thu7May
Actual outcome: Bear · $38.43 at outcome
Rapport reported a Q1 loss of $0.42 per share, which met or beat estimates, and provided positive clinical updates including accelerated timelines for its RAP-219 Phase 2 bipolar mania trial. Despite these positive developments, the stock fell below the $39.00 bear floor, likely driven by profit-taking following a 230% surge over the past year and recent significant insider selling as the company prepares for costly Phase 3 trials.
On May 15, 2026, Rapport is expected to report Q1 2026 earnings and update cash runway. From a base price of $44.00, a clean print with R&D spend aligned to RAP-219 Phase 3 plans and runway comfortably past key readouts could support a move to $46.00, while higher-than-expected burn or hints of upcoming financing could pull the stock back toward $46.00.
- Tue10Mar
Actual outcome: Bear · $27.84 at outcome
Rapport Therapeutics reported in-line Q4 2025 earnings with an EPS of -$0.72 and announced a strategic collaboration with Tenacia Biotechnology for RAP-219 in Greater China. The company also highlighted RAP-219's Phase 2a trial results and expected Phase 3 initiation in Q2 2026, but despite these pipeline updates, the stock fell 6.0% following the report.